Omnes Capital's investments
Pherecydes Pharma SA specializes in research into innovative and adaptive solutions to fight multi-resistant bacterial infections, using cocktails of natural phages.
Thanks to its unique expertise, Pherecydes Pharma has managed to develop a large bank of bacteriophages cocktails to fight antibiotic-resistant infections, steadily on the rise since the 1980s.
Founded in 2016, Octimet Oncology N.V. (Belgium) is a new company (spin-off from Johnson & Johnson) that acts as a translational accelerator, focusing on creating value for investors and patients by providing rapid clinical proof of concept for cancer therapies through innovative clinical development strategies and patient centered biomarker approaches. The current focus is on its clinical stage asset OMO-1, a highly selective small molecule MET inhibitor that will be developed with specific biomarkers, whilst an additional late pre-clinical stage oncology asset 0MO-2 will also enter the portfolio.